EUVIMEDEUVIMED entdecken
Open Access

Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice

Martina Beretta, Yumin Dai, Ellen M Olzomer, Calum S Vancuylenburg, José A Santiago-Rivera, Ashleigh M Philp, Stefan R Hargett, Keyong Li, Divya P Shah, Sing-Young Chen, Stephanie J Alexopoulos, Catherine Li und 11 weitere

Diabetes · 01.03.2024 · 73 (3) · 374-384

DOI: 10.2337/db23-0233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, online erschienen am 23.10.2023. Verfasst von Martina Beretta und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, New South Wales, Australia. Hauptthemen laut MEDLINE: Glucose Intolerance, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, CSR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excess body fat is a risk factor for metabolic diseases and is a leading preventable cause of morbidity and mortality worldwide. There is a strong need to find new treatments that decrease the burden of obesity and lower the risk of obesity-related comorbidities, including cardiovascular disease and type 2 diabetes. Pharmacologic mitochondrial uncouplers represent a potential treatment for obesity through their ability to increase nutrient oxidation. Herein, we report the in vitro and in vivo characterization of compound SHD865, the first compound to be studied in vivo in a newly discovered class of imidazolopyrazine mitochondrial uncouplers. SHD865 is a derivative of the furazanopyrazine uncoupler BAM15. SHD865 is a milder mitochondrial uncoupler than BAM15 that results in a lower maximal respiration rate. In a mouse model of diet-induced adiposity, 6-week treatment with SHD865 completely restored normal body composition and glucose tolerance to levels like those of chow-fed controls, without altering food intake. SHD865 treatment also corrected liver steatosis and plasma hyperlipidemia to normal levels comparable with chow-fed controls. SHD865 has maximal oral bioavailability in rats and slow clearance in human microsomes and hepatocytes. Collectively, these data identify the potential of imidazolopyrazine mitochondrial uncouplers as drug candidates for the treatment of obesity-related disorders. Article Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucose IntoleranceDiabetes Mellitus, Type 2MiceRatsHumansAnimalsAdiposityObesityLiverDiet, High-FatMice, Inbred C57BL

Autor:innen und Institutionen

  • School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, New South Wales, Australia.
  • Department of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, VA.
  • St Vincent's Clinical School, UNSW Medicine, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Pharmacology, University of Virginia, Charlottesville, VA.
  • Biological Resources Imaging Laboratory, University of New South Wales, Sydney, New South Wales, Australia.
  • Life Biosciences, Boston, MA.

ORCID-Profile: Thurl E Harris, Webster L Santos, Kyle L Hoehn

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • CSR NIH HHS
  • Life Biosciences
  • Center for Scientific Review
  • National Health and Medical Research Council

Zitieren

APA

Beretta, M., Dai, Y., Olzomer, E. M., Vancuylenburg, C. S., Santiago-Rivera, J. A., Philp, A. M., Hargett, S. R., Li, K., Shah, D. P., Chen, S. Y., Alexopoulos, S. J., Li, C., Harris, T. E., Lee, B., Wathier, M., Cermak, J. M., Tucker, S. P., Turner, N., Bayliss, D. A., …, & Hoehn, K. L. (2024). Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice. Diabetes, 73(3), 374-384. https://doi.org/10.2337/db23-0233

Vancouver

Beretta M, Dai Y, Olzomer EM, Vancuylenburg CS, Santiago-Rivera JA, Philp AM, et al. Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice. Diabetes. 2024;73(3):374-384. doi:10.2337/db23-0233

BibTeX
@article{Beretta2024,
  author = {Beretta, Martina and Dai, Yumin and Olzomer, Ellen M and Vancuylenburg, Calum S and Santiago-Rivera, José A and Philp, Ashleigh M and Hargett, Stefan R and Li, Keyong and Shah, Divya P and Chen, Sing-Young and Alexopoulos, Stephanie J and Li, Catherine and Harris, Thurl E and Lee, Brendan and Wathier, Michel and Cermak, Jennifer M and Tucker, Simon P and Turner, Nigel and Bayliss, Douglas A and Philp, Andrew and Byrne, Frances L and Santos, Webster L and Hoehn, Kyle L},
  title = {Liver-Selective Imidazolopyrazine Mitochondrial Uncoupler SHD865 Reverses Adiposity and Glucose Intolerance in Mice},
  journal = {Diabetes},
  year = {2024},
  volume = {73},
  number = {3},
  pages = {374--384},
  doi = {10.2337/db23-0233}
}
Kostenlos starten →